Eli Lilly and Company completed the acquisition of Akouos for $610m.

Eli Lilly and Company, a distributor of pharmaceutical products, completed the acquisition of Akouos, a genetic medicine company, for $610m. "I am proud of the commitment and passion of our team, which has established Akouos as a pioneer in inner ear genetic medicine, as demonstrated by our work to advance the first investigational therapy for a genetic form of hearing loss into clinical development. Joining Lilly – a company that shares our purpose to make life better for people around the world – will help us accelerate the development of a broad pipeline of inner ear genetic medicines," Emmanuel Simons, Akouos Co-Founder, President and CEO.